Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Japan Could Miss Out on Wave 1 of Drug Development, Re-Do and Do Right on PMP: PhRMA
With the planned scale-down of the so-called price maintenance premium (PMP) to be carried out in April, Japan might not be able to maintain its position to be in the first wave of global clinical trials, the Pharmaceutical Research and…
To read the full story
Related Article
- PhRMA/EFPIA Rap Japan’s Drug Pricing Reform, Warn of Grave Consequences
December 21, 2017
- PhRMA/EFPIA to Govt: Make Major Changes to Drug Pricing Proposal, It Will Tarnish Japan’s Reputation
December 11, 2017
- PhRMA Stands Pat on PMP Push, Says Minor Modification to Govt Proposal “Far from Sufficient”
December 8, 2017
- Maintain Drug Prices for Duration of Patent Coverage, PhRMA/EFPIA Stress at Chuikyo
November 30, 2017
ORGANIZATION
- Industry Hails Japan Growth Roadmap, PhRMA Urges Follow-Through
June 25, 2026
- Boehringer’s Hasson Appointed EFPIA Japan Vice Chair
June 22, 2026
- Think Tank Opposes Cap on Social Security Burden Ratio, Urges Pause in Off-Year Price Cuts
June 22, 2026
- Japanese Drug Makers Step Up Use of ASEAN Reliance Reviews
June 18, 2026
- Ease Foreign Price Adjustment Rules for New Drugs to Counter MFN Policy: FPMAJ
June 15, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…